The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials.
 
Yada Kanjanapan
No Relationships to Disclose
 
Daphne Day
No Relationships to Disclose
 
Lisa Wang
No Relationships to Disclose
 
Aaron Richard Hansen
Honoraria - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Merck Serono; Pfizer
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Albiruni Ryan Abdul Razak
Honoraria - Boehringer Ingelheim
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Merck
Research Funding - Amgen; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; CASI Pharmaceuticals; Deciphera; Karyopharm Therapeutics; Lilly; MedImmune; Novartis; Pfizer; Roche/Genentech
 
Anna Spreafico
Consulting or Advisory Role - Novartis
Research Funding - Bristol-Myers Squibb; Merck; Novartis
 
Natasha B. Leighl
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
 
Anthony M. Joshua
No Relationships to Disclose
 
Marcus O. Butler
Honoraria - Bristol-Myers Squibb; Merck; Novartis; Roche
Consulting or Advisory Role - Adaptimmune; Bristol-Myers Squibb; EMD Serono; GlaxoSmithKline; Immunocore; Immunovaccine; Merck; Novartis
Research Funding - Merck
Expert Testimony - Merck
 
David Hogg
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono; Merck; Novartis; Roche/Genentech
 
Lillian L. Siu
Leadership - Agios (I)
Consulting or Advisory Role - AstraZeneca/MedImmune; Merck; MorphoSys; Symphony Evolution
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Symphony Evolution (Inst)
 
Philippe L. Bedard
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cascadian Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); PTC Therapeutics (Inst); Sanofi (Inst); SERVIER (Inst); SignalChem (Inst)